CEO Chris Gibson highlighted the company's strategic focus on the Recursion Operating System 2.0, emphasizing its capability to improve efficiency in drug discovery and development. Management ...

Earnings call Recursion Pharmaceuticals delivered strong operational progress with a 30% YoY reduction in operating expenses and an extended cash runway into early 2028. Clinical momentum was ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...

Recursion Pharmaceuticals exceeded EPS expectations by 15.38%. The company reported a significant revenue shortfall, missing forecasts by 60.26%. Pre-market stock price fell 1.84% amid broader biotech ...

Multiple clinical programs from Recursion’s first generation platform are on track to read out Phase 2 data in H2 2024 and H1 2025 with additional second generation programs approaching IND in the ...

Hello, everybody, and welcome to Recursion's Third Quarter 2025 (L)earnings Call. My name is Chris Gibson. I'm the Co-Founder and current CEO of Recursion, and I'm so delighted to have you all joining ...